How to reconstitute MOTS-c: a practical, careful protocol

Last updated 2026-07-24

What does reconstituting MOTS-c actually mean?

Reconstitution is just the process of turning freeze-dried (lyophilized) peptide powder back into a liquid you can draw into a syringe. MOTS-c ships as a white or off-white powder in a sealed glass vial, usually 5 mg or 10 mg. On its own, that powder isn't injectable. You add a sterile liquid, most commonly bacteriostatic water (BAC water), swirl it gently until it dissolves, and now you have a solution at a known concentration. The biology behind the peptide is genuinely interesting. MOTS-c is a 16-amino acid peptide encoded in the mitochondrial genome, first shown in 2015 to regulate metabolic homeostasis and reduce obesity and insulin resistance in mouse models ^[1]. A 2018 Cell Metabolism paper found it translocates to the nucleus under metabolic stress and directly regulates nuclear gene expression, which is unusual for a mitochondrial peptide ^[2]. None of that changes the mechanics of mixing a vial, but it's worth knowing you're handling a research compound with a real, if early, scientific story, not a wellness powder with a marketing story bolted onto nothing. One thing reconstitution does not do: it doesn't make the product sterile if it wasn't already, and it doesn't make dosing decisions for you. Those are separate problems, covered below.

What do you need before you start?

Basic supplies: the vial of lyophilized MOTS-c, bacteriostatic water (not plain sterile water, and not saline), alcohol swabs, a syringe with a draw needle for mixing, and a fine-gauge insulin syringe if you're planning subcutaneous injection afterward. You want a clean, flat surface and ideally to work over a paper towel in case of drips. Bacteriostatic water matters specifically because it contains 0.9% benzyl alcohol as a preservative, which suppresses bacterial growth in the vial across multiple uses. Plain sterile water has no preservative, so a vial mixed with it is technically single-use and should be discarded same-day. Most people reconstituting multi-dose peptide vials use BAC water for that reason. It's sold at pharmacies and through compounding channels; it is not itself a controlled substance, but it is a sterile injectable product and should be treated with the same hygiene standards as anything else going into a syringe. Skip the tap water, skip the bottled water, skip anything not labeled sterile and pharmaceutical grade. This is not the place to improvise.

How much bacteriostatic water should you add to a MOTS-c vial?

There's no single official number here because MOTS-c isn't an FDA-approved drug with a package insert (nothing in the Drugs@FDA database matches it) ^[3]. What exists instead is a range of common practice drawn from how peptide vials are generally handled. A frequently used approach for a 10 mg vial is 2 mL to 3 mL of bacteriostatic water, which gives a concentration of roughly 5 mg/mL to 3.3 mg/mL. For a 5 mg vial, 1 mL to 2 mL is common, landing around 5 mg/mL to 2.5 mg/mL. More water means a more dilute solution and larger injection volumes for the same dose, which some people prefer because it's easier to measure small amounts accurately on an insulin syringe. Less water means a more concentrated solution and smaller injection volumes, which some prefer for comfort or fewer injections. Neither is 'more correct' in an absolute sense. What matters is that you do the math correctly and stay consistent. Here's the arithmetic laid out for a 10 mg vial:

A standard insulin syringe reads in units where 100 units equals 1 mL. If your math gives you a dose under 3-4 units, consider adding less water so your working volume is larger and easier to measure precisely. For a detailed walkthrough of the dose math itself, our mots-c 10mg dosage calculator works through several vial sizes side by side, and our mots-c dosage page covers what doses actually appear in the published research (almost entirely rodent studies, worth saying again).

What's the actual step-by-step reconstitution process?

Wipe the top rubber stopper of the MOTS-c vial with an alcohol swab and let it air dry for a few seconds. Draw your chosen amount of bacteriostatic water into a syringe, checking for air bubbles and tapping them out. Insert the needle through the center of the stopper at a slight angle and inject the water down the inside wall of the vial, not directly onto the powder. This slows the flow and prevents a hard, fast stream from foaming the peptide or creating turbulence that can shear delicate molecular structure. Once the water is in, don't shake the vial. Swirl it gently, or let it sit for a minute and then roll it between your palms. Most peptide powders dissolve within a minute or two. If you see cloudiness, visible particles, or the powder resists dissolving after several minutes of gentle swirling, don't use that vial. That's a sign of a problem with the peptide, the water, or a contamination issue, and it isn't something to troubleshoot by force.

How do I know if reconstituted MOTS-c has gone bad?

Look at it. A properly mixed and stored solution should stay clear and colorless. Cloudiness, visible flecks, or a color change from clear to yellow or brown are all signs to discard the vial. Peptides degrade through oxidation and hydrolysis over time, faster at room temperature and faster still with light exposure or repeated freeze-thaw cycles. Most compounded peptide guidance suggests refrigerating reconstituted vials at 2-8°C and using the contents within roughly 20-30 days, though this window is a general compounding-pharmacy convention rather than a number pinned down by a MOTS-c-specific stability study. Nobody has published a formal stability dataset for reconstituted MOTS-c at various temperatures and timeframes that we're aware of, so this range is inference from peptide handling practice broadly, not a citation-backed MOTS-c fact. Don't freeze reconstituted peptide. Freezing and thawing cycles are one of the more reliable ways to degrade peptide structure, and a frozen-then-thawed vial should be treated with suspicion even if it looks fine.

Where should reconstituted MOTS-c be stored?

Refrigerator door shelves see the most temperature swings every time the door opens, so the back of a middle shelf, consistently in the 2-8°C range, is a better spot. Keep the vial upright, away from light, in its original box if it has one. If you're traveling, small insulated pouches with an ice pack can hold the vial in range for several hours. Avoid direct ice contact against the glass, which can occasionally cause the vial to crack from cold stress, and never let it sit in a hot car or direct sun even briefly. Peptide degradation accelerates a lot faster with heat than most people expect; a few hours at 30°C+ can do more damage than weeks at proper refrigeration.

Does the 'exercise in a pill' framing hold up once you look at the studies?

This is probably the single most repeated claim about MOTS-c online, and it deserves a direct answer: no published study demonstrates MOTS-c is an 'exercise mimetic' in humans in any FDA-recognized or clinically validated sense. That phrase is marketing shorthand for a real but narrower finding. What's actually shown: a 2022 review in Diabetes & Metabolism Journal discusses MOTS-c as part of the broader mitohormesis response, the process by which mild mitochondrial stress (including from exercise) triggers adaptive signaling ^[4]. A related 2021 paper reviewed mitochondrial-derived peptides and exercise specifically, describing how circulating MOTS-c levels change with physical activity in the contexts studied ^[5]. Separately, a 2025 study found MOTS-c 'mimics exercise' to combat diabetic liver fibrosis in a rodent model by targeting the Keap1-Nrf2-Smad2/3 pathway ^[6]. That's a real, specific, mechanistic finding, in mice, about liver fibrosis, not a general statement that injecting MOTS-c gives you the cardiovascular, muscular, and neurological benefits of a training program. The foundational 2015 Cell Metabolism paper that started a lot of the interest showed MOTS-c administration reduced obesity and insulin resistance and promoted metabolic homeostasis in mice fed a high-fat diet ^[1]. Mice on a high-fat diet losing weight and improving insulin sensitivity with a peptide is a legitimately interesting result. It is not the same claim as 'MOTS-c replaces exercise in humans.' Treat that phrase, wherever you see it, as compressed marketing language sitting on top of real but narrow rodent biology.

What does the human evidence for MOTS-c actually look like?

Thin. That's the honest one-word answer, and it's worth sitting with rather than glossing over. The large majority of MOTS-c findings, including everything cited in this article so far, come from mouse models, cell culture, or in vitro systems. A 2023 Frontiers in Endocrinology review frames MOTS-c as 'a promising mitochondrial-derived peptide for therapeutic exploitation,' language that itself signals early-stage, pre-clinical status rather than an established therapy ^[7]. A separate 2023 Metabolites paper titled 'MOTS-c Functionally Prevents Metabolic Disorders' reports findings in that same pre-clinical frame ^[8]. A 2026 Sports Medicine paper specifically reviewing peptide therapies used for musculoskeletal injuries and athletic performance, covering both approved and unapproved compounds, is one of the more relevant recent looks at how these peptides are actually being used in practice outside the lab ^[9]. That paper's inclusion of MOTS-c among 'unapproved' peptide therapies is itself informative: it signals that regulatory and safety oversight lags well behind the compound's popularity in performance and longevity circles. Separately, it's worth flagging a genuinely contrarian data point: a 2018 Rejuvenation Research paper reported that mitochondrial-derived peptides, as a class, can under some conditions exacerbate senescence rather than reduce it ^[10]. That's not a MOTS-c-specific death knell, but it's a reminder that 'mitochondrial peptide' is not automatically synonymous with 'anti-aging,' and the biology can cut both directions depending on context, dose, and tissue.

What is MOTS-c legally, and can it be compounded?

MOTS-c is not an FDA-approved drug. A search of the Drugs@FDA database, the agency's official record of approved drug products, turns up no MOTS-c entry ^[3]. That means there is no FDA-reviewed dosing, no FDA-reviewed safety profile, and no FDA-reviewed manufacturing standard specific to this peptide. Compounding pharmacies operate under two different sections of federal law depending on their structure. Section 503A pharmacies, governed by 21 U.S.C. 353a, can compound preparations for individual patients with a prescription, but only using bulk substances on an approved list or nominated for one ^[11][12][13]. Section 503B outsourcing facilities work from a separate bulks list under 21 CFR 216.24 ^[14]. As of current FDA guidance, checking the bulk drug substances nominated for compounding list is the relevant step for anyone trying to understand MOTS-c's regulatory footing ^[13]. This is a moving target; substance status on these lists changes as FDA reviews nominations, so the honest answer is to check the current list rather than rely on a fixed claim. The practical upshot: sourcing quality varies enormously across suppliers, and 'reconstitute correctly' assumes you started with a peptide that was actually manufactured to a real purity standard in the first place. That's a sourcing question, not a mixing question, and it deserves its own scrutiny. Our mots-c peptide buy guide covers what to check before you ever pick up a vial.

What about injection technique once MOTS-c is reconstituted?

Reconstitution and injection are two different skills, and getting the mixing right doesn't automatically mean the injection is done well. MOTS-c in published animal studies has generally been administered by injection rather than orally, consistent with how most peptides are handled (oral bioavailability for a 16-amino-acid peptide is poor because gut enzymes break it down before absorption). Subcutaneous injection, typically into the abdomen or thigh, using a fine insulin needle, is the common approach people use. Rotate injection sites to avoid localized irritation or lipohypertrophy (fatty lumps from repeated injections in the same spot). Draw the correct volume based on your reconstitution math above, expel air bubbles, pinch a skin fold, and inject at roughly 90 degrees for standard subcutaneous depth with a short insulin needle. Our mots-c peptide injection piece walks through site rotation, needle gauge choice, and common technique mistakes in more depth. For a look at what side effects have actually been reported or are mechanistically plausible, see mots-c side effects.

What mistakes actually ruin a vial, and how do you avoid them?

Shaking the vial hard is the most common one. Vigorous agitation can denature peptide structure through mechanical shear and foaming, effectively wasting the vial even though it looks fine. Swirl gently or let it sit. Using the wrong diluent is second. Bacteriostatic saline, plain sterile water without preservative, or anything not labeled for injection each carry different problems, from lack of antimicrobial protection to incompatibility with the peptide. Stick with bacteriostatic water specifically. Injecting the diluent too fast, directly onto the powder, can create a jet that damages the peptide on contact and also causes excessive foaming that makes it hard to judge whether full dissolution has happened. Slow, wall-directed flow avoids both problems. Last, reusing a needle that's touched anything else, or drawing from a vial with a needle that's already been used multiple times, raises contamination risk with every additional puncture. Fresh, sterile needle for the water draw is a small cost against a real risk.

What should you do if you're actually considering using MOTS-c?

Read the mechanistic story, understand it's early, and be honest with yourself about the gap between mouse metabolic data and a therapy calibrated for humans. The 2015 Cell Metabolism paper and the 2018 nuclear translocation paper are the two most-cited foundational studies, and both are rodent and cell-based work, not clinical trials ^[1][2]. If your mental model of MOTS-c is 'clinically proven exercise mimetic,' that model is wrong; if your model is 'a genuinely interesting mitochondrial signaling peptide with dozens of pre-clinical papers across metabolism, muscle, bone, lung, and even ovarian cancer models, and essentially no controlled human trial data,' that's accurate ^[15][16]. If you decide to go ahead anyway, the sourcing decision matters more than the reconstitution technique, because no amount of careful mixing fixes a vial that wasn't pure or accurately dosed to begin with. MOTS-c Co reviews providers against sourcing and lab-testing criteria and can point you toward routes that use provider oversight and a named, accountable compounding pharmacy partner, rather than anonymous vials with no chain of custody. That's a meaningfully different risk profile than an unmarked package from an unverifiable seller, even though neither route involves an FDA-approved product. Whatever route you take, keep records: lot number, reconstitution date, water volume used, and storage conditions. If anything goes wrong, that log is the only way to reconstruct what happened.

Frequently asked questions

How much bacteriostatic water do I add to a 10 mg MOTS-c vial?

Common practice is 2 mL to 3 mL, giving roughly 5 mg/mL to 3.3 mg/mL. There's no FDA-approved package insert for MOTS-c specifying an official amount, since it isn't an FDA-approved drug, so this range reflects general peptide-handling convention rather than a validated protocol.

Can I use regular water or saline instead of bacteriostatic water?

No. Plain sterile water has no preservative and turns the vial into a single-use product that should be discarded same-day. Bacteriostatic water contains 0.9% benzyl alcohol, which allows safer multi-dose use across several weeks when refrigerated.

How long does reconstituted MOTS-c last in the fridge?

General compounding practice suggests roughly 20-30 days when refrigerated at 2-8°C, but this is a convention borrowed from peptide handling broadly, not a number from a MOTS-c-specific stability study. Discard sooner if you see cloudiness or color change.

Should I shake the vial to help the powder dissolve?

No. Shaking can shear and denature the peptide structure through mechanical stress and foaming. Swirl gently or roll the vial between your palms; most peptide powder dissolves within a minute or two without force.

Is MOTS-c actually an 'exercise mimetic'?

That's marketing language, not a clinical finding. Studies show MOTS-c is involved in mitohormesis, the adaptive signaling triggered by exercise-like mitochondrial stress, and one 2025 rodent study found it mimics exercise effects specifically in diabetic liver fibrosis via Keap1-Nrf2-Smad2/3 signaling. That is a narrow, mechanistic result, not proof it replaces training in humans.

Is MOTS-c FDA approved?

No. A search of the Drugs@FDA database shows no approved MOTS-c product. It has no FDA-reviewed dosing, safety profile, or manufacturing standard, and any use falls outside approved-drug regulatory protections.

Can MOTS-c be legally compounded by a pharmacy?

Compounding pharmacies must use bulk substances from FDA's approved or nominated lists under 21 U.S.C. 353a and related bulks lists (21 CFR 216.23 for 503A, 216.24 for 503B). Whether MOTS-c currently qualifies depends on its status on FDA's nominated bulk substances list, which changes over time, so check the current list rather than assuming a fixed answer.

What does the research actually show MOTS-c does?

Mostly rodent and cell-based findings: reduced obesity and insulin resistance in mice (2015, Cell Metabolism), nuclear gene regulation under metabolic stress (2018, Cell Metabolism), effects on muscle atrophy, bone metabolism, lung injury, and even ovarian cancer progression in pre-clinical models. No large human clinical trial has established a validated human dose or outcome.

What if the reconstituted solution looks cloudy or has particles?

Discard it. Clear and colorless is the expected appearance; cloudiness, flecks, or a shift to yellow/brown signal degradation or contamination. This applies whether the change happens right after mixing or weeks into refrigerated storage.

Where should I inject reconstituted MOTS-c?

Subcutaneous injection into the abdomen or thigh with a fine insulin needle is the common approach in practice, mirroring how most research peptides are handled. Rotate sites to avoid irritation or lipohypertrophy from repeated injections in the same spot.

Can MOTS-c be taken orally instead of injected?

Not effectively. As a 16-amino-acid peptide, MOTS-c has poor oral bioavailability because digestive enzymes break it down before it can be absorbed intact, which is why published studies use injection rather than oral dosing.

Does freezing reconstituted MOTS-c extend its shelf life?

No, avoid freezing. Freeze-thaw cycles are a common cause of peptide degradation and structural damage. Consistent refrigeration at 2-8°C, not freezing, is the standard storage approach for reconstituted peptide vials.

Why do some MOTS-c protocols use less water and some use more?

More diluent gives a lower concentration and larger injection volumes, which some find easier to measure precisely on an insulin syringe; less diluent gives a higher concentration and smaller volumes, preferred by some for fewer or smaller injections. Neither is objectively correct; consistency in your own math matters more than the specific ratio chosen.

Sources

1. Cell Metabolism, 2015 (PMID 25738459): MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in mouse models
2. Cell Metabolism, 2018 (PMID 29983246): MOTS-c translocates to the nucleus and regulates nuclear gene expression in response to metabolic stress
3. Drugs@FDA database: MOTS-c has no FDA-approved drug product listing
4. Diabetes & Metabolism Journal, 2022 (PMID 35656563): MOTS-c is discussed as part of the mitohormesis response linked to exercise-induced mitochondrial stress
5. Biochimica et Biophysica Acta, 2021 (PMID 34520826): Review of mitochondrial-derived peptides including MOTS-c in relation to exercise
6. Scientific Reports, 2025 (PMID 40425777): MOTS-c mimics exercise to combat diabetic liver fibrosis via Keap1-Nrf2-Smad2/3 signaling in a rodent model
7. Frontiers in Endocrinology, 2023 (PMID 36761202): MOTS-c is described as a promising mitochondrial-derived peptide for therapeutic exploitation, signaling early-stage status
8. Metabolites, 2023 (PMID 36677050): MOTS-c functionally prevents metabolic disorders in pre-clinical research
9. Sports Medicine, 2026 (PMID 41966639): Review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, including MOTS-c's unapproved status
10. Rejuvenation Research, 2018 (PMID 30058454): Mitochondrial-derived peptides can exacerbate senescence under some conditions
11. 21 U.S.C. 353a, pharmacy compounding: Federal statute governing 503A pharmacy compounding requirements including bulk substance sourcing
12. 21 CFR 216.23, the final 503A Bulks List: Regulation listing bulk drug substances approved for 503A compounding
13. FDA, bulk drug substances nominated for use in compounding: Current FDA list of bulk drug substances nominated for compounding use, relevant to MOTS-c's regulatory status
14. 21 CFR 216.24, the 503B Bulks List: Regulation listing bulk drug substances for 503B outsourcing facility compounding
15. iScience, 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
16. Advanced Science, 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination in pre-clinical models